The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2020.20045
Abstract: BACKGROUND Larotrectinib and entrectinib are FDA-approved therapies for patients with non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase gene fusion (TRK fusion-positive) whose cancer has metastasized and progressed. Early evidence indicates that these… read more here.
Keywords: larotrectinib entrectinib; life; trk fusion; larotrectinib ... See more keywords